

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

POLL RESULTS OF THE RESOLUTIONS PASSED AT THE 2025 ANNUAL GENERAL MEETING AND A SHAREHOLDERS' CLASS MEETING

References are made to circular of Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”) dated 29 April 2026 (the “**Circular**”) and the notice of the 2025 annual general meeting dated 29 April 2026 (the “**Notice**”). Unless the context requires otherwise, terms used herein shall have the same respective meanings as those defined in the Circular and the Notice.

CONVENING AND ATTENDANCE OF THE MEETINGS

The 2025 Annual General Meeting and the A Shareholders' Class Meeting (the “**Meetings**”) of the Company were held at 2:00 p.m. on Tuesday, 26 May 2026 at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tongzhou District, Beijing, the PRC.

The Meetings were convened by the board of Directors of the Company (the “**Board**”) and chaired by Ms. Shi Wenling, chairman of the Board. Voting at the Meetings were conducted by a combination of internet voting and registered poll onsite. WUYIGE Certified Public Accountants LLP, the Company's auditor, was appointed by the Company as the scrutineer for the voting.

The convening of the Meetings were in compliance with the requirements of the applicable laws and regulations of the PRC, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the articles of association of the Company.

The total number of issued Shares of the Company as at the date of the 2025 Annual General Meeting was 383,568,500 Shares, including (i) 288,428,000 A Shares, out of which 1,376,851 A Shares were treasury shares held by the Company (the “**Treasury Shares**”); and (ii) 95,140,500 H Shares. The Treasury Shares were excluded from the total number of Shares entitling the A Shareholders to attend and vote for or against or abstain from voting on the resolutions proposed at the 2025 Annual General Meeting and the A Shareholders’ Class Meeting. Therefore, the total number of eligible Shares that entitled the Shareholders to attend and vote for or against or abstain from voting on the resolutions proposed at the 2025 Annual General Meeting was 382,191,649 Shares, and the total number of eligible Shares that entitled the A Shareholders to attend and vote for or against or abstain from voting on the resolution proposed at the A Shareholders’ Class Meeting was 287,051,149 Shares. No party has stated its intention in the Circular that it would vote against any resolution at the Meetings.

As disclosed in the Circular, Mr. Shi Chunbao (the executive Director and controlling shareholder of the Company), holding 120,209,043 Shares of the Company in aggregate (115,473,043 A Shares and 4,736,000 H Shares) and Ms. Yue Shujun (the executive Director, deputy general manager and controlling shareholder of the Company) holding 95,447,900 Shares of the Company in aggregate (95,447,900 A Shares and 0 H Shares) were required to abstain and have abstained from voting in respect of resolution 6 at the 2025 Annual General Meeting. As such, the aggregate number of Shares entitling Shareholders to attend the 2025 Annual General Meeting and vote for or against resolution 6 was 166,534,706 Shares representing approximately 43.57% of the Company’s total share capital in issue.

Saved as disclosed above, to the best knowledge, information and belief of the Directors of the Company, there was no restriction on any Shareholder casting votes on any of the proposed resolutions at the Meetings. There were no Shares entitling the Shareholders to attend the Meetings and abstain from voting in favor as set out in Rule 13.40 of the Listing Rules and no Shareholders were required under the Listing Rules to abstain from voting at the Meetings.

All Directors attended the Meetings. The attendance record of the Directors at the Meetings was as follows:

- the executive Directors of the Company, Ms. Shi Wenling and Mr. Xie Feng Bao attended the Meetings in person; and
- the executive Directors of the Company, Mr. Shi Chunbao and Ms. Yue Shujun, the non-executive Director, Mr. Wang Xin, and the independent non-executive Directors of the Company, Ms. Xu Hong, Mr. Wong Tak Shing and Mr. Weng Jie attended the Meetings by telephone.

Details about the attendance of the Shareholders and their authorized proxies at the Meetings are set out as follows:

	Class of Shares	Number of Shareholders and authorised proxies attending the Meetings	Total number of the A Shares/ H Shares held by the attendees	Percentage of A Shares/H Shares held by the attendees to the total number of the Company's Shares with voting rights
The 2025 Annual General Meeting	A Shares	43	214,138,508	56.0291%
	H Shares	1	19,742,887	5.1657%
The A Shareholders' Class Meeting	A Shares	43	214,138,508	74.5994%*

* Percentage of the total number of A Shares with voting rights

POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING

The poll results of the resolutions proposed at the 2025 Annual General Meeting are as follows:

Ordinary resolutions		Number of votes & percentage of the total voting shares at the 2025 Annual General Meeting (%)		
		For	Against	Abstained
1.	To consider and approve the annual report for 2025 and its summary	233,816,542 (99.9723%)	52,285 (0.0224%)	12,568 (0.0054%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
2.	To consider and approve the proposed profit distribution plan for 2025	233,816,542 (99.9723%)	62,853 (0.0269%)	2,000 (0.0009%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
3.	To consider and approve the 2025 performance report of the independent non-executive Directors	233,808,802 (99.9690%)	52,285 (0.0224%)	20,308 (0.0087%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			

Ordinary resolutions		Number of votes & percentage of the total voting shares at the 2025 Annual General Meeting (%)		
		For	Against	Abstained
4.	To consider and approve the report of the Board of Directors for 2025	233,808,802 (99.9690%)	52,285 (0.0224%)	20,308 (0.0087%)
As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.				
5.	To consider and approve the financial report for the year 2025	233,808,802 (99.9690%)	52,285 (0.0224%)	20,308 (0.0087%)
As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.				
6.	To consider and approve the remuneration of the Directors of the Company for 2026	18,150,858 (99.5962%)	71,594 (0.3928%)	2,000 (0.0110%)
As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.				
7.	To consider and approve the appointment of auditors (domestic and overseas) and internal control auditor for 2026	233,816,542 (99.9723%)	52,285 (0.0224%)	12,568 (0.0054%)
As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.				
Special resolution		Number of votes & percentage of the total voting shares at the 2025 Annual General Meeting (%)		
		For	Against	Abstained
8.	To consider and approve the grant of the general mandate to the Board of Directors to repurchase the H Shares of the Company	233,815,541 (99.9718%)	63,854 (0.0273%)	2,000 (0.0009%)
As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.				

POLL RESULTS OF THE A SHAREHOLDERS' CLASS MEETING

The poll results in respect of the resolution proposed at the A Shareholders' Class Meeting are as follows:

Special resolution		Number of votes & percentage of the total voting shares at the A Shareholders' Class Meeting (%)		
		For	Against	Abstained
1.	To consider and approve the grant of the general mandate to the Board of Directors to repurchase the H Shares of the Company	214,072,654 (99.9692%)	63,854 (0.0298%)	2,000 (0.0009%)
As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.				

For the full text of the resolutions, please refer to the Circular of the Company dated 29 April 2026.

PAYMENT OF FINAL DIVIDEND

The Board announces that the proposal of payment of final dividend of RMB1.50 per 10 Shares in cash (tax inclusive) for the year ended 31 December 2025 (“**Final Dividend**”) to all Shareholders was approved at the 2025 Annual General Meeting.

In order to determine the Shareholders who are entitled to the receipt of the Final Dividend, the Final Dividend will be distributed to those Shareholders whose names appear on the register of members of the Company on 1 June 2026 in respect of H Shares. In order to qualify for receiving the Final Dividend, all transfer documents accompanied by the relevant share certificates must be lodged with the Company's H Share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (for holders of H Shares) no later than 4:30 p.m. on 29 May 2026.

The Final Dividend will be paid to holders of A Shares in RMB and to holders of H Shares in HK dollar. The actual amount of H Share dividend paid in HK dollar will be calculated according to the average exchange rate of the relevant foreign exchange published by the People's Bank of China the mid-rate of seven business days prior to the date of approval of Final Dividend in 2025 Annual General Meeting. The average exchange rate of the relevant foreign exchange published by the People's Bank of China for the mid-rate of seven business days prior to the date of approval of Final Dividend in 2025 Annual General Meeting (i.e. 14 May 2026 to 22 May 2026) is RMB1/HK\$1.14516. Applying that average, the dividend for each H Share is HK\$0.17177.

The Company will withhold and pay the income tax strictly in accordance with the relevant laws or requirements of the relevant government authorities. For more information about the withholding tax, please refer to the Circular.

LEGAL ADVISERS AS TO PRC LAWS

The Meetings were witnessed by lawyers from V&T Law Firm, Beijing, the PRC legal adviser of the Company, who concluded that the convening and convening procedures of the Meetings are in compliance with the relevant requirements of the laws, administrative regulations and the articles of association of the Company. The eligibilities of the attendees, the convener of the Meetings and the procedures and results of voting at the Meetings were legal and valid.

POSTPONEMENT OF THE H SHAREHOLDERS' CLASS MEETING

The H Shareholders' Class Meeting which was originally scheduled to be held at 2:00 p.m. (or immediately after the conclusion of the A Shareholders' Class Meeting) on Tuesday, 26 May 2026 has been adjourned and will be held at 2:00 p.m. on Friday, 5 June 2026 (the "**Adjourned H Shareholders' Class Meeting**"). Please refer to the announcement published by the Company on 25 May 2026 for more details.

Implementation of the matters relating to resolution no. 8 of the 2025 Annual General Meeting and resolution no. 1 of the A Shareholders' Class Meeting is subject to the approval of the H Shareholders attending the Adjourned H Shareholders' Class Meeting on Friday, 5 June 2026.

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Shi Wenling
Chairman

Beijing, the PRC, 26 May 2026

As at the date of this announcement, the executive Directors of the Company are Mr. Shi Chunbao, Ms. Yue Shujun, Ms. Shi Wenling and Mr. Xie Feng Bao; the non-executive Director of the Company is Mr. Wang Xin; and the independent non-executive Directors of the Company are Ms. Xu Hong, Mr. Wong Tak Shing and Mr. Weng Jie.

* *For identification purpose only*